A novel strategy for hemolytic uremic syndrome: successful treatment with thrombomodulin α.

@article{Honda2013ANS,
  title={A novel strategy for hemolytic uremic syndrome: successful treatment with thrombomodulin α.},
  author={Takashi Honda and Shohei Ogata and Eri Mineo and Yukako Nagamori and Shinya Nakamura and Yuki Bando and Masahiro Ishii},
  journal={Pediatrics},
  year={2013},
  volume={131 3},
  pages={
          e928-33
        }
}
Hemolytic uremic syndrome (HUS) is a life-threatening infectious disease in childhood for which there is no confirmed therapeutic strategy. Endothelial inflammation leading to microthrombosis formation via complement activation is the main pathology of HUS. Thrombomodulin is an endothelial membrane protein that has anticoagulation and anti-inflammatory effects, including the suppression of complement activity. Recombinant human soluble thrombomodulin (rTM) is a novel therapeutic medicine for… CONTINUE READING
6
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice.

  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2015
VIEW 2 EXCERPTS
CITES BACKGROUND

Management of hemolytic uremic syndrome

VIEW 1 EXCERPT
CITES BACKGROUND

[Hemolytic uremic syndrome as of 2013].

  • Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
  • 2013
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 11 REFERENCES

Copyright © 2013 by the American Academy of Pediatrics

Grove Village, Illinois
  • 2013

Eculizumab in severe Shigatoxinassociated HUS

AL Lapeyraque, M Malina, V Fremeaux-Bacchi
  • N Engl J Med
  • 2011